Literature DB >> 22609889

Large-scale comparison of Roche Cobas AmpliPrep/Cobas TaqMan and Abbott RealTime HIV assays.

Michael T Pyne1, Andrew Wilson, David R Hillyard.   

Abstract

Significant underquantitation of HIV RNA has been reported with the Roche Cobas AmpliPrep/Cobas TaqMan HIV Test (Version 1) compared to other assays. However, these studies have generally involved limited numbers of samples from select patient populations or analysis of samples that were undetectable in the TaqMan assay. Random plasma samples submitted from throughout the United States for HIV RNA quantitation (n=1263) were compared in the Roche TaqMan and Abbott RealTime assays. Twenty-four samples (1.9%) were discrepant, with a maximum difference between the two assays of 1.9logcopies/mL. These data indicate that both tests may be susceptible to underquantitation, but the incidence is low in this large cohort of samples from across the United States.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609889     DOI: 10.1016/j.jviromet.2012.05.007

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  3 in total

1.  European Multicenter Study on Analytical Performance of Veris HIV-1 Assay.

Authors:  Patrick Braun; Rafael Delgado; Monica Drago; Diana Fanti; Hervé Fleury; Jörg Hofmann; Jacques Izopet; Ulrich Kalus; Alessandra Lombardi; Maria Angeles Marcos; Davide Mileto; Karine Sauné; Siobhan O'Shea; Alfredo Pérez-Rivilla; John Ramble; Pascale Trimoulet; Jordi Vila; Duncan Whittaker; Alain Artus; Daniel W Rhodes
Journal:  J Clin Microbiol       Date:  2017-04-19       Impact factor: 5.948

2.  Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots.

Authors:  Malaya K Sahoo; Vici Varghese; Elizabeth White; Meg Winslow; David A Katzenstein; Robert W Shafer; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2016-08-17       Impact factor: 5.948

3.  Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.

Authors:  Timothy J Henrich; Brian R Wood; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.